Empagliflozin as a Novel Therapy in Refractory Ascites

Sponsor
Alexandria University
Study ID
NCT05430243
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Ascites Hepatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    once daily empagliflozin 10mg+/- diuretics
  • Diuretics — DRUG
    diuretics as clinically indicated

Study Details

The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients with liver cirrhosis

Key Dates

Start date
Apr 21, 2022
Status verified
Nov 2022
Primary completion
Nov 12, 2022
Completion
Nov 12, 2022

Study Design

Enrollment
42 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin group
  • Active Comparator: standard treatment only group

Primary Outcome Measure

No need for paracentecis [ Time Frame: 3 months ]

Related Studies